Table 1. Patient Demographics.
| DTX | DTX+ADT | p value | |
|---|---|---|---|
| Number of patients | 21 | 26 | NS |
| Thrombocytopenia | 69 (67-74) | 68 (63-72) | 0.459 |
| BMI (kg/m2) | 24.0 (22.5-25.4) | 24.2 (23.3-26.6) | 0.708 |
| ECOG PS ≥1, n (%) | 8 (38.1) | 15 (57.7) | 0.181 |
| Gleason score at diagnosis, n (%) | |||
| ≤8 | 8 (38.1) | 8 (30.8) | 0.598 |
| ≥9 | 13 (61.9) | 18 (69.2) | 0.598 |
| Clinical T stage at diagnosis, n (%) | |||
| ≤T3 | 14 (66.7) | 15 (57.7) | 0.529 |
| T4 | 7 (33.3) | 11 (42.3) | 0.529 |
| Clinical N stage at diagnosis, n (%) | |||
| N1 | 13 (61.9) | 14 (53.8) | 0.579 |
| Prior treatment, n (%) | |||
| Radical prostatectomy | 5 (23.8) | 6 (23.1) | 1.000 |
| Definitive EBRT | 0 (0.0) | 1 (3.8) | 1.000 |
| Palliative EBRT | 7 (33.3) | 9 (34.6) | 0.927 |
| Duration of ADT prior to DTX | 12 (7-32.5) | 10.5 (7-31.5) | 0.464 |
| Response to primary ADT | |||
| PSA nadir (ng/mL) | 2.3 (0.4-14.5) | 0.7 (0.2-7.8) | 0.380 |
| PSA velocity (ng/mL/yr) | 28.9 (6.7-252.1) | 33.5 (14.6-158.9) | 0.906 |
| PSA doubling time (ng/mL/yr) | 0.16 (0.11-0.42) | 0.18 (0.09-0.30) | 0.700 |
| Laboratory values | |||
| PSA at diagnosis (ng/mL) | 68.9 (29.7-449.0) | 85.2 (25.4-262.0) | 0.881 |
| PSA at CRPC diagnosis (ng/mL) | 41.5 (26.9-112.0) | 42.2 (28.8-173.4) | 0.966 |
| Hb (g/dL) | 11.6 (10.8-12.9) | 11.9 (10.9-13.0) | 0.676 |
| NLR | 2.06 (1.39-3.64) | 2.28 (1.57-4.13) | 0.341 |
| Albumin (g/dL) | 4.1 (3.8-4.6) | 4.2 (3.6-4.4) | 0.772 |
| Number of DTX cycles | 7 (6-11) | 9.5 (5-12) | 0.643 |
| Extent of disease at CRPC diagnosis, n (%) | |||
| Bone metastasis | 18 (85.7) | 25 (96.2) | 0.311 |
| Lymph node metastasis | 15 (71.4) | 17 (65.4) | 0.659 |
| Lung or liver metastasis | 1 (4.8) | 1 (3.8) | 1.000 |
DTX, docetaxel-based chemotherapy; ADT, androgen deprivation therapy; BMI, body mass index; ECOG, Eastern Cooperative Oncology Group; PS, performance status; EBRT, external-beam radiation therapy; PSA, prostate-specific antigen; CRPC, castration-resistant prostate cancer; Hb, hemoglobin; NLR, neutrophil-tolymphocyte ratio.
Data are median (interquartile range) and number (%).